Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

This publication has 13 references indexed in Scilit:

• Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
  American Journal of Kidney Diseases, 2000
• Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis
  New England Journal of Medicine, 2000
• A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
  American Journal of Kidney Diseases, 1999
• RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
  Kidney International, 1999
• Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
  American Journal of Kidney Diseases, 1997
• Coronary Artery Calcification: Pathophysiology, Epidemiology, Imaging Methods, and Clinical Implications
  Circulation, 1996
• Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study
  Kidney International, 1996
• Alternative phosphate binders: an update
  Nephrology Dialysis Transplantation, 1993
• FRACTURING DIALYSIS OSTEODYSTROPHY AND DIALYSIS ENCEPHALOPATHY: An Epidemiological Survey
  Published by Elsevier ,1979
• The Dialysis Encephalopathy Syndrome
  New England Journal of Medicine, 1976